Health Condition 1: null- Multidrug-Resistant Tuberculosis Health Condition 2: A15- Respiratory tuberculosis
Conditions
Interventions
Intervention1: Bedaquiline (TMC207): Bedaquiline (TMC207) tablet formulation administered orally as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 200 mg 3 tim
Sponsors
Janssen Research Development LLC
Eligibility
Inclusion criteria
Inclusion criteria: 1. Participant must be a boy or girl, aged from birth (0 months) to less than 18 years at screening. Infants must be greater than or equal to 37 weeks gestation at baseline 2. Participant must weigh more than 4 kilogram (kg) at entry and be within the 5th and 95th percentiles (inclusive) for the participantâ??s age, based on the World Health Organization (WHO) child growth standards; Body Mass Index (BMI) for age 3. Heterosexually active girls may participate if they are of non-childbearing potential, or if they are using effective birth control methods and are willing to continue practicing birth control methods throughout Multidrug Resistant Tuberculosis (MDR-TB) treatment and for 6 months after stopping TMC207 treatment, or if they are non-heterosexually active or willing to practice sexual abstinence throughout MDR-TB treatment 4. Boys who engage in sexual activity that could lead to pregnancy of the female partner must use at minimum a male condom throughout MDR-TB treatment and for 3 months after stopping TMC207 treatment 5. Participants must be starting the initial MDR-TB regimen at baseline or have started an MDR-TB regimen within 8 weeks of baseline and are willing to modify it if necessary to an acceptable MDR-TB regimen for use with TMC207 6. Participant must be willing to permanently discontinue RMP from at least 7 days before the baseline visit
Exclusion criteria
Exclusion criteria: 1. Participant has a clinically significant active medical condition or the presence of any concomitant severe illness or rapidly deteriorating health condition, including immune deficiency, which in the opinion of the investigator would prevent 2. appropriate participation in the study, or that would make implementation of the protocol or interpretation of the study results difficult, or otherwise make the subject a poor candidate for a clinical study 3. Participant is a girl who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 6 months after stopping TMC207 treatment 4. Participant (or the mother if the potential subject is a child aged 5. Participant has known or presumed complicated or severe extrapulmonary manifestations of TB, including TB meningitis. Participants with adenopathy or adenitis are allowed to enter the study 6. Participant has a significant cardiac arrhythmia that requires medication or a history of risk factors for Torsade de Pointes, example heart failure, hypokalemia, known personal or family history of Long QT Syndrome, and untreated hypothyroidism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a) Number of Participants With Adverse Events or Serious Adverse Events b) Maximum Plasma Concentration c) Time to Reach Maximum Plasma Concentration d) Minimum Plasma Concentration e) Area Under the Plasma Concentration-time Curve From the Time of Dose Administration up to X Hours f) Elimination Half-life g) Area Under the Plasma Concentration-time Curve From the Time of Dose Administration up to 168 Hours h) Volume of Distribution i) Apparent Clearance (CL)Timepoint: a) 120 weeks b) Day 1,week 2,4,6,8,12,16,20,24 c) Day 1,week 2,4,6,8,12,16,20,24 d) Day 1, week 2, 4,6,8,12,16,20,24,28,32,40,48,60,72,84,96,108,120 e) Day 1, week 2, 4,6,8,12,16,20,24,28,32,40,48,60,72,84,96,108,120 f) Day 1, week 2, 4,6,8,12,16,20,24,28,32,40,48,60,72,84,96,108,120 g) Pre-dose (time 0) at Day 1 up to 168 hour h) Day 1, week 2, 4,6,8,12,16,20,24,28,32,40,48,60,72,84,96,108,120 i) Day 1, week 2, 4,6,8,12,16,20,24,28,32,40,48,60,72,84,96,108,120 | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of Participants with Favorable Treatment outcome (Sustained Positive Clinical Cure)Timepoint: Week 24, Week 120 (end of study);Time to First Confirmed Sputum Culture Conversion or Other Microbiology Specimen SampleTimepoint: Baseline (Day 1) up to Week 120 | — |
Countries
India, Philippines, Russian Federation, South Africa
Contacts
Public ContactDr Jitendra Dixit
Johnson & Johnson Private Limited
Outcome results
None listed